Evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg compared with each monotherapy
Not Applicable
Recruiting
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0001405
- Lead Sponsor
- G Life Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 285
Inclusion Criteria
1)Patient with type 2 Diabetes Mellitus and Dyslipidemia
2)Adults aged = 19 years old
Exclusion Criteria
1)Patients with Type 1 Diabetes, Patients with Diabetic Ketoacidosis or Diabetic Coma as well as Pre-coma
2)Patients with Gestational Diabetes Mellitus or with Secondary Diabetes
3)Patients with NYHA Class III, IV Congestive Heart Failure or with Treatment-requiring Arrhythmia
4)Patients with Thyroid Dysfunction whose TSH is out of normal range with treatment
5)Patients with pituitary insufficiency or hypoadrenalism
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c change ;LDL-C change rate
- Secondary Outcome Measures
Name Time Method ipid parameters (HDL, TG, TC) change